Department of Nuclear Medicine, Loyola University Medical Center, Maywood, IL, USA.
Clin Nucl Med. 2011 Aug;36(8):e72-80. doi: 10.1097/RLU.0b013e318224b814.
This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.
本指南旨在指导经过适当培训和许可的医生使用未密封放射性药物源进行治疗。遵守本指南应有助于最大限度地提高这些程序的有效性，保持安全条件，并确保符合适用法规。本指南涉及的主题包括碘-131 的使用指征，包括治疗甲状腺功能亢进和甲状腺癌。此外，其他不太常见的程序的适应症包括使用液体和胶体形式的磷-32、锶-89、钐-153 以及使用 Y-90 抗体。
